Tanioka H, Kaga K
Department of Radiology, Tanioka Clinic, Kashiwa, Japan.
J Int Med Res. 1996 Jan-Feb;24(1):88-91. doi: 10.1177/030006059602400111.
Adult patients with symptoms of gastric disease were randomly assigned to two treatment groups (roxatidine group, n = 115; famotidine group, n = 113) or untreated control group (placebo, n = 111). The treatment groups randomly received 75 mg of roxatidine or 20 mg of famotidine at 9 pm, and 12 - 13 h later gastric juice secretion was measured with gastric X-ray films in both groups. Mean gastric juice secretion was significantly lower in the treated groups (roxatidine, 16.1 ml/12 h; famotidine, 19.9 ml/12 h) than in the untreated controls (placebo, 49.5 ml/12 h). Gastric juice suppression by roxatidine and by famotidine, respectively, was 82% and 37% in patients with gastric ulcer; 71% and 39% in patients with duodenal ulcer; 70% and 64% in patients with gastritis; and 68% and 86% in patients with no evidence of disease. It is concluded that roxatidine was more effective than famotidine for gastric juice suppression in patients with peptic ulcer. In patients with no evidence of gastric disease, however, famotidine was more effective than roxatidine.
有胃病症状的成年患者被随机分为两个治疗组（罗沙替丁组，n = 115；法莫替丁组，n = 113）或未治疗的对照组（安慰剂组，n = 111）。治疗组在晚上9点随机接受75毫克罗沙替丁或20毫克法莫替丁，12 - 13小时后用胃X光片测量两组的胃液分泌量。治疗组（罗沙替丁组，16.1毫升/12小时；法莫替丁组，19.9毫升/12小时）的平均胃液分泌量显著低于未治疗的对照组（安慰剂组，49.5毫升/12小时）。罗沙替丁和法莫替丁对胃溃疡患者胃液的抑制率分别为82%和37%；对十二指肠溃疡患者分别为71%和39%；对胃炎患者分别为70%和64%；对无疾病证据的患者分别为68%和86%。结论是，在消化性溃疡患者中，罗沙替丁在抑制胃液方面比法莫替丁更有效。然而，在无胃病证据的患者中，法莫替丁比罗沙替丁更有效。
